Literature DB >> 35530526

Preparation, Characterization, and Cell Uptake of PLGA/PLA-PEG-FA Nanoparticles.

Heng Yang1, Junsik Sung2, Zahra Alghoul3, Didier Merlin2,4.   

Abstract

Oral administration of colon-targeting nanoformulations holds many advantages over the systemic delivery of free drugs, or traditional nontargeting formulations in the treatment of ulcerative colitis (UC). Currently, the most conventional method for constructing colon-targeting drug delivery systems (DDS) is by integrating the biocompatible materials poly(lactic-co-glycolic acid) (PLGA) and polylactic acid (PLA) into a copolymer. This PLGA/PLA-polyethylene glycol-folic acid (PEG-FA) copolymeric nanoformulation effectively delivers the drugs for uptake by various human colon cancer cells (e.g., HT-29 and HCT-116) and mouse colon cancer cells (CT-26). There is, however, a distinct lack of comprehensive protocols for the construction of such copolymer. This protocol details an easy-to-follow single-step method for the construction of a colon-targeting PLGA/PLA-PEG-FA nanoformulation, which encapsulates a fluorescent dye and demonstrates the visualization of its cell uptake in vitro.
Copyright © 2022 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Anti-inflammatory; Colon; Drug delivery; Inflammatory bowel disease; Nanoparticles; PLGA/PLA-PEG-FA; Ulcerative colitis

Year:  2022        PMID: 35530526      PMCID: PMC9018435          DOI: 10.21769/BioProtoc.4373

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  5 in total

1.  Local antitumor effects of intratumoral delivery of rlL-2 loaded sustained-release dextran/PLGA-PLA core/shell microspheres.

Authors:  Haiping Zhao; Fei Wu; Yunpeng Cai; Yinghui Chen; Liangming Wei; Zhenguo Liu; Weien Yuan
Journal:  Int J Pharm       Date:  2013-04-25       Impact factor: 5.875

Review 2.  New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance.

Authors:  Kartikeya Tripathi; Joseph D Feuerstein
Journal:  Drugs Context       Date:  2019-04-29

3.  Oral Delivery of Nanoparticles Loaded With Ginger Active Compound, 6-Shogaol, Attenuates Ulcerative Colitis and Promotes Wound Healing in a Murine Model of Ulcerative Colitis.

Authors:  Mingzhen Zhang; Changlong Xu; Dandan Liu; Moon Kwon Han; Lixin Wang; Didier Merlin
Journal:  J Crohns Colitis       Date:  2018-01-24       Impact factor: 9.071

4.  Natural-lipid nanoparticle-based therapeutic approach to deliver 6-shogaol and its metabolites M2 and M13 to the colon to treat ulcerative colitis.

Authors:  Chunhua Yang; Mingzhen Zhang; Sudeep Lama; Lixin Wang; Didier Merlin
Journal:  J Control Release       Date:  2020-04-23       Impact factor: 9.776

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.